Gary Remington, MD, PhD, FRCPC
- 20Articles
- 79.2KReads
- 1999–2018Active
- 61Collaborators
- 527Citations
About
Gary Remington, MD, PhD, FRCPC, has contributed extensively to the fields of schizophrenia, schizoaffective disorders, mood disorders, movement disorders, and psychopharmacology. His publications from 1999 to 2018 include studies on antipsychotic medications such as aripiprazole, clozapine, risperidone, and valbenazine, with a focus on treatment strategies, pharmacokinetics, and clinical outcomes. He has also investigated suicide risk in schizophrenia and the management of tardive dyskinesia. His work often involves clinical trials and observational studies addressing illness severity and medication effects.
Publications
Quantifying Intraindividual Variations in Plasma Clozapine Levels: A Population Pharmacokinetic Approach
May 25, 2016
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.
